PURPOSE: To evaluate the efficacy and @entity137 of @entity136 ( @entity136 ) in previously untreated @entity1 with @entity1606 . @entity1 AND METHODS: Forty-one @entity1 with measurable @entity1606 who had received no prior chemotherapy for metastatic disease were scheduled to receive @entity136 1,200 mg/m2 intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Prior adjuvant or neoadjuvant therapy for locally advanced disease was allowed if this was completed greater than 1 year prior to study entry. All @entity1 were treated on an outpatient basis. RESULTS: There were three complete responses and six partial responses seen in 37 assessable @entity1 , for an overall response rate of nine of 37 (24.3%; 95% confidence interval, 12 to 41). Four @entity1 remain in remission at 14, 23, 24, and 31 months. The median survival was 8 months with 17% of @entity1 alive at 2 years. Treatment generally was well-tolerated with three @entity1 having > or = grade 3 nonhematologic @entity137 , five having grade 3 @entity1398 , two having grade 3 @entity882 , and two episodes of @entity1398 . Most @entity1 were able to receive the drug as scheduled with the primary reason for dose reduction or dose delay being @entity1398 . CONCLUSION: @entity136 has promising single-agent activity against @entity5 with a favorable @entity137 profile. Further studies in combination with other active agents are warranted.

XXXX : a promising new agent in the treatment of advanced @entity5 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urothelial cancer'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['advanced transitional cell carcinoma'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine', "2',2'-difluorodeoxycytidine"]
@entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']
